Diagnosing the Biotech Breakdown - Presented by: The Aol. On Network

Biotechs have been taking a beating- losing their huge momentum in the last week- after gains of more than 250 percent in the last five years. One of the triggers of the sell-off: lawmakers' questions about Gilead Science's pricing of its new Hepatitis C drug- it's been getting pushback from insurers. Questions about price panicked investors, and now the bubble is bursting says Josh Brown, CEO of Ritholtz Wealth Management.



Related Videos

Most Popular Videos

Latest Videos


Most Active by Volume

Company Last Sale Change Net / %
AAPL $ 97.19 2.47 ▲ 2.61%
FB $ 71.29 2.02 ▲ 2.92%
MSFT $ 44.87 0.04 ▲ 0.09%
EMC $ 28.75 0.23 ▲ 0.81%
BAC $ 15.52 unch
SIRI $ 3.46 0.02 ▼ 0.57%
JNPR $ 22.43 2.39 ▼ 9.63%
YHOO $ 34.71 1.11 ▲ 3.30%

As of 7/23/2014, 04:04 PM
More Most Active